EP2568811A4 - TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER - Google Patents

TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER

Info

Publication number
EP2568811A4
EP2568811A4 EP10851531.3A EP10851531A EP2568811A4 EP 2568811 A4 EP2568811 A4 EP 2568811A4 EP 10851531 A EP10851531 A EP 10851531A EP 2568811 A4 EP2568811 A4 EP 2568811A4
Authority
EP
European Patent Office
Prior art keywords
tcl
alzheimer
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10851531.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2568811A1 (en
Inventor
Mark Lovell
Bert Lynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Original Assignee
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/034721 external-priority patent/WO2010132671A1/en
Application filed by University of Kentucky Research Foundation filed Critical University of Kentucky Research Foundation
Publication of EP2568811A1 publication Critical patent/EP2568811A1/en
Publication of EP2568811A4 publication Critical patent/EP2568811A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10851531.3A 2010-05-13 2010-11-18 TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER Withdrawn EP2568811A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2010/034721 WO2010132671A1 (en) 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease
PCT/US2010/057287 WO2011142778A1 (en) 2010-05-13 2010-11-18 Treatment of mci and alzheimer's disease

Publications (2)

Publication Number Publication Date
EP2568811A1 EP2568811A1 (en) 2013-03-20
EP2568811A4 true EP2568811A4 (en) 2014-03-12

Family

ID=44923820

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10851531.3A Withdrawn EP2568811A4 (en) 2010-05-13 2010-11-18 TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER

Country Status (6)

Country Link
EP (1) EP2568811A4 (https=)
JP (1) JP2013526518A (https=)
CN (1) CN102984938A (https=)
AU (1) AU2010353287A1 (https=)
CA (1) CA2799162A1 (https=)
WO (1) WO2011142778A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2994160T (lt) * 2013-05-06 2019-08-26 Baxalta Incorporated Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
CN111426848A (zh) 2013-06-28 2020-07-17 株式会社 Mcbi 认知功能障碍疾病的生物标记物及使用该生物标记物的认知功能障碍疾病的检测方法
JP6276865B2 (ja) * 2014-01-29 2018-02-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アリールラクタムキナーゼ阻害剤
CN106177046A (zh) * 2016-08-29 2016-12-07 杨添福 一种基于普立宁钾开发的神经认知障碍治疗药物及其制备方法
CN106645505A (zh) * 2016-11-18 2017-05-10 中国医科大学 可实现glt‑1蛋白鉴定及绝对定量的试剂盒及测定方法
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
CN106636388A (zh) * 2016-12-15 2017-05-10 湖南中能荆卫生物科技有限公司 用于亨廷顿病诊断的基因及其应用以及由其编码的蛋白和蛋白的应用
CN108191966B (zh) * 2018-01-11 2020-10-27 桂林医学院 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽
KR20220004618A (ko) * 2019-01-07 2022-01-11 세나 바이오사이언스 아이엔씨. 신규한 펩티드 및 이의 용도
JP7321017B2 (ja) * 2019-07-17 2023-08-04 東海物産株式会社 機能性食品

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028761A1 (en) * 1999-08-16 2002-03-07 Koppel Gary A. Neurotherapeutic use of carboxypeptidase inhibitors
WO2010034110A1 (en) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
WO2010108052A2 (en) * 2009-03-20 2010-09-23 H. Lundbeck A/S Amide derivatives as neuropeptide y5 receptor ligands

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8002A (en) * 1851-03-25 Upright pianoforte
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
US6558650B1 (en) * 1998-04-08 2003-05-06 Oregon Health And Science University Enhancement of cellular gallium uptake
CN1479616A (zh) * 2000-11-21 2004-03-03 霍华德・齐克 使用1,4-二氢吡啶钙通道阻断剂治疗疱疹神经病毒病症
WO2005051389A1 (en) * 2003-11-21 2005-06-09 Memory Pharmaceuticals Corporation Using of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dymethyl-pyridine-3,5-dicarboxylate in the treatment of memory disorders
EP1874311B1 (en) * 2005-04-15 2011-10-05 Research & Innovation S.p.A. A method for preventing, delaying or reverting abnormal amyloid deposition
US20090286879A1 (en) * 2005-12-02 2009-11-19 Kiyoshi Hashizume Preventive or Therapeutic Drug for Alzheimer-Type Dementia
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
CA2648243C (en) * 2006-04-11 2015-12-22 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
WO2008109613A1 (en) * 2007-03-05 2008-09-12 Wyeth Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028761A1 (en) * 1999-08-16 2002-03-07 Koppel Gary A. Neurotherapeutic use of carboxypeptidase inhibitors
WO2010034110A1 (en) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
WO2010108052A2 (en) * 2009-03-20 2010-09-23 H. Lundbeck A/S Amide derivatives as neuropeptide y5 receptor ligands

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DONG H. KIM: "Rearrangements of 4-(2-Aminophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 23, no. 5, 1 September 1986 (1986-09-01), US, pages 1471 - 1474, XP055100273, ISSN: 0022-152X, DOI: 10.1002/jhet.5570230543 *
DONNA L SAVIGNI ET AL: "Iron and transition metal transport into erythrocytes mediated by nifedipine degradation products and related compounds", BIOCHEMICAL PHARMACOLOGY, vol. 65, no. 8, 1 April 2003 (2003-04-01), pages 1215 - 1226, XP055100193, ISSN: 0006-2952, DOI: 10.1016/S0006-2952(03)00045-5 *
GÖRLITZER K ET AL: "3,6-Diazaphenanthrene aus Nifedipin", ARCHIV DER PHARMAZIE, WILEY VERLAG, WEINHEIM, vol. 318, no. 2, 1 February 1985 (1985-02-01), pages 97 - 105, XP002668333, ISSN: 0365-6233 *
GÖRLITZER K ET AL: "9-Chlor-3,6-diazaphenanthrene aus Nifedipin", ARCHIV DER PHARMAZIE, WILEY VERLAG, WEINHEIM, vol. 318, no. 2, 1 January 1985 (1985-01-01), pages 106 - 110, XP002668334, ISSN: 0365-6233 *
KAMETANI T ET AL: "NITRENES. PART III. THE REACTION OF 4-(2-NITROPHENYL)PYRIDINE DERIVATIVES WITH TRIETHYL PHOSPHITE", JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY, CHEMICAL SOCIETY. LETCHWORTH, GB, 1 January 1969 (1969-01-01), pages 138 - 140, XP009004598, ISSN: 0022-4952, DOI: 10.1039/J39690000138 *
PETROW V A: "New Syntheses of Heterocyclic Compounds. Part VIII. The Schmidt Rearrangement of 1 : 3-Dimethyl-2-azafluorenones (continued)", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL SOCIETY, LETCHWORTH; GB, 1 January 1946 (1946-01-01), pages 888 - 891, XP002668516, ISSN: 0368-1769 *
See also references of WO2011142778A1 *

Also Published As

Publication number Publication date
EP2568811A1 (en) 2013-03-20
CN102984938A (zh) 2013-03-20
AU2010353287A1 (en) 2012-11-29
WO2011142778A1 (en) 2011-11-17
CA2799162A1 (en) 2011-11-17
JP2013526518A (ja) 2013-06-24

Similar Documents

Publication Publication Date Title
EP2568811A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
EP2408434A4 (en) TREATMENT OF MORBUS ALZHEINER AND OSTEOPOROSE AND REDUCTION OF AGING
EP2672927A4 (en) TREATMENT OF HERZOHR OCKLUSIONS AND ARRHYTHMIES
EP2793993A4 (en) RECOVERY AND PROCESSING OF HUMAN IN VIVO EMBRYOS
EP2555765A4 (en) TREATMENT OF LOUIS BAR SYNDROME
EP2542255A4 (en) METHOD AND COMPOSITIONS FOR TREATING THE DEGOS SYNDROME
EP2391316A4 (en) TREATMENT OF GRAVITY
EP2387611A4 (en) DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDERS
EP2519234A4 (en) ANAPLEROTIC THERAPY FOR MORBUS ALZHEIMER AND BRAIN AGING
EP2665479A4 (en) METHOD AND MEDICAMENT PRODUCTS FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2582683A4 (en) TREATMENT OF GAS AND HYPERURICEMIA
EP2911664A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
EP2307035A4 (en) TREATMENT OF EPILEPSY
EP2819687A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PERIPHERAL VASCULAR DISEASES
EP2872899A4 (en) TESTING ON MORBUS ALZHEIMER IN A LIVING PATIENT
EP2780082A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2483417A4 (en) METHOD FOR DIAGNOSIS AND / OR TREATMENT OF ENZEPHALITIS OR EPILEPSY
EP2536468A4 (en) TREATMENT OF CHRONIC INFLAMMATORY DISEASES
EP2729148A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON
EP2389388A4 (en) TREATMENT OF ADIPOSITAS
EP2550263A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP2858517A4 (en) TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES AND THROMBOSIS
EP2978446A4 (en) METHOD AND MEANS FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2429992A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
EP2582391A4 (en) ARTHRITIS TREATMENT

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1183408

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20140211

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 43/40 20060101AFI20140205BHEP

Ipc: A61P 25/28 20060101ALI20140205BHEP

Ipc: A61K 31/4375 20060101ALI20140205BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160601

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1183408

Country of ref document: HK